[1]张璐,韩俊泉,王红.名中医王红治疗代谢相关脂肪性肝病临床经验[J].陕西中医,2025,46(6):813-817.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.019]
　ZHANG Lu,HAN Junquan,WANG Hong.WANG Hong’s clinical experience in treating metabolic associated fatty liver disease[J].,2025,46(6):813-817.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.019]
点击复制

名中医王红治疗代谢相关脂肪性肝病临床经验
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年6期
页码:
813-817
栏目:
名中医经验
出版日期:
2025-06-05

文章信息/Info

Title:
WANG Hong’s clinical experience in treating metabolic associated fatty liver disease
作者:
张璐; 韩俊泉; 王红
（天津中医药大学第二附属医院,天津 300250)
Author(s):
ZHANG Lu; HAN Junquan; WANG Hong
(Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine，Tianjin 300250，China）
关键词:
代谢相关脂肪性肝病; 土壅木郁; 肠道菌群; 胆汁酸; 线粒体; 脂肪酸过氧化; 黄连温胆汤; 治疗经验
Keywords:
Metabolic associated fatty liver disease; Earth stagnation and wood depression; Intestinal microbiota; Bile acid metabolism; Mitochondria; Fatty acid peroxidation; Huanglian Wendan decoction; Therapeutic experience
分类号:
R 575.5
DOI:
DOI:10.3969/j.issn.1000-7369.2025.06.019
文献标志码:
A
摘要:
代谢相关脂肪性肝病(MAFLD)是全身代谢功能紊乱累及肝脏的表现。中医学认为MAFLD与过食肥甘厚味和过逸少劳有关。现代医学研究发现肠道菌群紊乱、胆汁酸代谢异常、线粒体功能障碍和脂肪酸过氧化导致的二次打击均会加重MAFLD。王红教授提出MAFLD病位在肝，病因在脾，病机是脾土壅塞、内生湿热、反侮肝木的演变过程，符合“土壅木郁”理论，与现代医学的肠-肝轴致病通路和脂肪酸β氧化相关致病因素一致。基于“土壅木郁”理论和近年研究，王红教授应用黄连温胆汤调和脾胃、清化痰湿，破除土壅，促进肝木疏泄，缓解肝郁，从多通路、多靶点减少肝脏脂肪蓄积和过氧化引起的肝损伤，同时调节全身糖脂代谢，取得较好疗效。
Abstract:
Metabolic associated fatty liver disease is a manifestation of systemic metabolic dysfunction involving the liver.Traditional medicine believes that MAFLD is associated with eating too much fat and sweet，and less exercise.Modern medical research has found that intestinal microbiota disorders,abnormal bile acid metabolism,mitochondrial dysfunction and secondary blows caused by fatty acid peroxidation can all aggravate MAFLD.Professor WANG Hong proposed that MAFLD is located in the liver,the cause is in the spleen,and the pathogenesis is the evolution process of spleen soil congestion,generate dampness and heat internally,and resist liver wood,which is in line with the theory of “Earth stagnation and wood depression”,and is consistent with the pathogenic pathway of the intestinal -liver axis and the pathogenic factors related to fatty acid β oxidation in modern medicine.Based on the theory of “Earth stagnation and wood depression” and recent research,Professor WANG Hong uses Huanglian Wendan decoction to harmonize the spleen and stomach,clear phlegm and dampness,remove the earth stagnation,promote the excretion of liver wood,alleviate liver depression,and reduce liver fat accumulation and peroxidation-induced liver damage through multiple pathways and targets,and effectively regulates systemic carbohydrate and fat metabolism at the same time,and achieves good results.

参考文献/References:

[1]ESLAM M,NEWSOME P N,SARIN S K,et al.A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement[J].J Hepatol,2020,73(1):202-209.
[2]中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018版)[J].传染病信息,2018,31(5):393-402，420.
[3]YOUNOSSI Z M,MARCHESINI G,PINTO-CORTEZ H,et al.Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis:Implications for liver transplantation[J].Transplantation,2019,103(1):22-27.
[4]刘东敏,赵明君,孙晓红.从肝论治“双心疾病”探析[J].陕西中医药大学学报,2021,44(6):41-45.
[5]FEI N,BRUNEAU A,ZHANG X,et al.Endotoxin producers overgrowing in human gut microbiota as the causative agents for nonalcoholic fatty liver disease[J].mBio,2020,11(1):3263-3269.
[6]ARON-WISNEWSKY J,VIGLIOTTI C,WITJES J,et al.Gut microbiota and human NAFLD:Disentangling microbial signatures from metabolic disorders[J].Nat Rev Gastroenterol Hepatol,2020,17(5):279-297.
[7]NIKIFOROVA Y V,FADIEIENKO G D,GRIDNEV A E,et al.Features of intestinal microbiota in patients with nonalcoholic fatty liver disease:Effects on markers of inflammation and hepatic steatosis[J].Wiad Lek,2022,75(3):611-618.
[8]ARAGONES G,COLOM P M,AGUILAR C,et al.Circulating microbiota-derived metabolites:A liquid biopsy?[J].Int J Obes (Lond),2020,44(4):875-885.
[9]SHARPTON S R,SCHNABL B,KNIGHT R,et al.Current concepts,opportunities,and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease[J].Cell Metab,2021,33(1):21-32.
[10]许映红,凌大军,吴元祥,等.双环醇联合益生菌治疗非酒精性脂肪肝的效果及对脂代谢、肝功能的影响[J].肝脏,2024,29(2):223-226.
[11]ROMANO K A,MARTINEZ D C.Metabolic,epigenetic,and transgenerational effects of gut bacterial choline consumption[J].Cell Host Microbe,2017,22(3):279-290.
[12]SHI C,PEI M,WANG Y,et al.Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine[J].Biochem Biophys Res Commun,2022,594:1-7.
[13]郑昊龙,陈丝,宋囡,等.脾虚模型大鼠肠道菌群分布及时效性研究[J].中医杂志,2020,61(14):1262-1267.
[14]黄文武,彭颖,王梦月,等.四君子汤及其单味药水煎液对脾虚大鼠肠道菌群的调节作用[J].中国实验方剂学杂志,2019,25(11):8-15.
[15]王俊俊,蔡晓波,陆伦根.胆汁酸与非酒精性脂肪性肝病的关系[J].临床肝胆病杂志,2023,39(5):1166-1171.
[16]EVANGELAKOS I,HEEREN J,VERKADE E,et al.Role of bile acids in inflammatory liver diseases[J].Semin Immunopathol,2021,43(4):577-590.
[17]GILLARD J,CLERBAUX L,NACHIT M,et al.Bile acids contribute to the development of non-alcoholic steatohepatitis in mice[J].Jhep Rep,2022,4(1):100387.
[18]COLLINS S L,STINE J G,BISANZ J E,et al.Bile acids and the gut microbiota:Metabolic interactions and impacts on disease[J].Nat Rev Microbiol,2023,21(4):236-247.
[19]冯彬彬,韩俊泉,杨朝帅,等.基于“土壅木郁”理论探讨肠道菌群失调与胆固醇结石的相关性[J].北京中医药大学学报,2023,46(7):980-984.
[20]DI CIAULA A,CALAMITA G,SHANMUGAM H,et al.Mitochondria matter:Systemic aspects of nonalcoholic fatty liver disease (NAFLD) and diagnostic assessment of liver function by stable isotope dynamic breath tests [J].Int J Mol Sci,2021,22(14):7702.
[21]邵幼林,范建高.非酒精性脂肪性肝病患者肝脏脂肪的来源与去路[J].国际消化病杂志,2019,39(5):316-320.
[22]CHEN L,LI Y,SOTTAS C,et al.Loss of mitochondrial ATPase ATAD3A contributes to nonalcoholic fatty liver disease through accumulation of lipids and damaged mitochondria[J].J Biol Chem,2022,298(6):102008.
[23]全海燕,江兴,何璐.线粒体自噬在肝胰岛素抵抗中作用机制的研究进展[J].中国临床药理学与治疗学,2022,27(2):198-204.
[24]MA X,QIAN H,CHEN A,et al.Perspectives on mitochondriaer and mitochondria-lipid droplet contact in hepatocytes and hepatic lipid metabolism[J].Cells,2021,10(9):2273.
[25]潘琳琳,相宏杰,刘桂荣.理脾降浊方通过调控HIF-1α/PPARγ/BNIP3线粒体自噬途径改善小鼠非酒精性脂肪肝的机制研究[J].时珍国医国药,2024,35(8):1862-1867.
[26]杨萍,黄清杰,李喜香,等.中药通过调控信号通路影响能量代谢的研究进展[J].中成药,2024,46(11):3715-3720.
[27]DIXON E D,NARDO A D,CLAUDEL T,et al.The role of lipid sensing nuclear receptors (PPARs and LXR) and metabolic lipases in obesity,diabetes and NAFLD[J].Genes (Basel),2021,12(5):645.
[28]RAEMAN R.Inflammation:The straw that broke the NAFLD liver[J].Cell Mol Gastroenterol Hepatol,2022,13(4):1273-1274.
[29]CHEN Z,TIAN R,SHE Z,et al.Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease[J].Free Radic Biol Med,2020,152:116-141.
[30]NI H,YU L,ZHAO X,et al.Seed oil of rosa roxburghii tratt against non-alcoholic fatty liver disease in vivo and in vitro through PPAR alpha/PGC-1alpha-mediated mitochondrial oxidative metabolism[J].Phytomedicine,2022,98:153919.
[31]杨帆,魏小果,李娟,等.清肝降脂汤对体外诱导非酒精性脂肪肝细胞模型脂代谢和过氧化物酶体增殖物激活受体-α的调节作用研究[J].陕西中医,2024,45(10):1326-1329.
[32]叶穗林,成莎,叶玺.加味温胆汤治疗老年高血压及对趋化因子CX3CL1影响的研究[J].中国当代医药,2021,28(33):160-163.
[33]王家豪,花海兵,薛昊,等.古代经典名方温胆汤的研究进展及质量标志物的预测分析[J].世界科学技术-中医药现代化,2024,26(6):1528-1536.
[34]钱小情,周继旺,李诗国,等.黄连温胆汤对痰热互结证2型糖尿病合并非酒精性脂肪肝患者血糖、血脂指标影响[J].辽宁中医杂志,2023,50(9):155-159.
[35]孔庆旭.温胆汤加减治疗非酒精性脂肪性肝病的疗效及改善患者肝功能的临床研究[J].湖北中医杂志,2022,44(12):32-34.
[36]田苗,马伯艳,张贺,等.化瘀温胆汤对糖耐量低减大鼠肝细胞线粒体SOD及MDA水平的影响[J].中医药学报,2018,46(2):33-35.

相似文献/References:

[1]刘可佳,徐 帅,李娟娟,等.基于“人卧血归于肝”探讨睡眠障碍对代谢相关脂肪性肝病的影响[J].陕西中医,2023,(6):758.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.017]
　LIU Kejia,XU Shuai,LI Juanjuan,et al.The influence of sleep disorders on metabolic associated fatty liver disease based on “the blood flows back to the liver when the man lies down”[J].,2023,(6):758.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.017]
[2]黄玉迎,杨培伟,王晓杰,等.基于土壅木郁理论探讨铁死亡与代谢相关脂肪性肝病的关系[J].陕西中医,2024,(10):1395.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.022]
　HUANG Yuying,YANG Peiwei,WANG Xiaojie,et al.Exploration on relationship between ferroptosis and metabolism-associated fatty liver disease based on earth stagnation and wood depression[J].,2024,(6):1395.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.022]
[3]石丹丹,艾碧琛,李木兰,等.基于FXR/SHP/PEPCK和FXR/ApoCⅡ通路探讨茵陈五苓散对代谢相关脂肪性肝病大鼠糖脂代谢的作用[J].陕西中医,2025,46(2):153.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.002]
　SHI Dandan,AI Bichen,LI Mulan,et al.Effects of Yinchen Wuling powder on glycolipid metabolism in metabolic associated fatty liver disease rats based on FXR/SHP/PEPCK and FXR/ApoCⅡ pathways[J].,2025,46(6):153.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.002]

备注/Memo

备注/Memo:
国家自然科学基金资助面上项目(82274522)；天津市名中医传承工作室建设项目[津卫中（2023）469号]
更新日期/Last Update: 2025-06-09